GV

GV Management Company, LLC, formerly known as Google Ventures, serves as the venture capital arm of Alphabet Inc., established in 2009 and headquartered in Mountain View, California, with additional offices in Boston, New York, Cambridge, and London. The firm specializes in growth capital investments across various stages, including seed, early, mid, and late stages, focusing on sectors such as life sciences, healthcare, artificial intelligence, robotics, cyber security, and agriculture. GV has invested in over 300 companies, seeking to support startups that aim to innovate and transform industries. The firm typically invests up to $50 million, with smaller amounts allocated to early-stage ventures. GV provides its portfolio companies with exceptional support by connecting them with Google's resources and talent, leveraging a team of experts in engineering, design, science, and marketing to enhance their growth potential.

Karthik Ardhanareeswaran

Principal

Brian Bendett

Partner

Scott Biller

Venture Partner

Brendan Bulik-Sullivan

General Partner

A Marty Cannon

Founder and Managing Member

Sherry Chao

Principal

Tyson Clark

General Partner

Frederique Dame

Partner

Scott Davis

Venture Partner

Karim Faris

General Partner

Catherine J. Friedman

Executive Venture Partner

Cathy Friedman

Venture Partner

Anika Gupta

Principal

Han Hua

Principal

Crystal Huang

Partner

Tom Hulme

General Partner and Head of Europe

Rosana Kapeller

Investor

John Lyman

Partner

Michael Margolis

Partner

Laura Melahn

Partner

Dave Munichiello

Managing Partner

Erik Nordlander

General Partner

Sridhar Ramaswamy

Venture Partner

Leena Rao

Content Partner

David Reshef

Venture Partner

Ben Robbins

General Partner

Issi Rozen

Venture Partner

Elena Sakach

Investment Partner

Luna Schmid

Partner

Vidu Shanmugarajah

Partner

M.G. Siegler

General Partner

Graham Spencer

Managing Partner

Jon Stritar

Partner

Andy Wheeler

General Partner

Jeremy Whelchel

Partner

Sangeen Zeb

General Partner

Past deals in Series B

Cerevance

Series B in 2023
Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.

Flatfile

Series B in 2022
Flatfile Inc. offers a platform designed to streamline the data onboarding process for businesses by allowing developers to validate, map, and import data from various web applications. Founded in 2018 and based in Denver, Colorado, the company's key products include Portal, an import button that integrates seamlessly into software applications through a JavaScript snippet, and Concierge, which provides secure workspaces for collaboration on data ingestion challenges. Flatfile's platform supports multiple file formats, including CSV, XLS, and TSV, and features a JavaScript configurator that enables users to define target models for data validation. This automation helps organizations manage and structure imported data effectively, reducing the time spent on data cleaning and allowing teams to focus on utilizing their data for decision-making.

Sardine

Series B in 2022
FinTech, RegTech, Fraud Operating System

Merlin Labs

Series B in 2022
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.

Courier

Series B in 2022
Courier provides an API that enables developers to manage and route user notifications across various communication channels, such as email and messaging platforms. By leveraging user engagement data and online status, the API optimizes notification delivery, ensuring that messages reach users through the most effective medium. The company's notification management software allows clients to create reusable messages that can be customized for different channels, facilitating timely and targeted communication. Over the years, Courier has adapted to technological advancements while maintaining a stable management approach, emphasizing the importance of customer success. The company has developed long-lasting relationships with its largest clients, continually collaborating to meet their evolving needs.

Sesame

Series B in 2022
Sesame, Inc., operating as SesameCare, is a company that offers a platform for booking doctor appointments and accessing medical care. Founded in 2018 and based in New York, SesameCare aims to simplify the healthcare experience by connecting patients directly with doctors, providing upfront pricing and clear descriptions of medical services. This approach is particularly beneficial for uninsured individuals or those opting to pay out-of-pocket, as it addresses common issues such as hidden costs and unexpected charges that often complicate healthcare access. By focusing on transparency and affordability, SesameCare endeavors to make quality healthcare more accessible for all patients.

Nava

Series B in 2022
Nava is a New York-based company that specializes in health insurance brokerage services aimed at delivering high-quality, affordable healthcare solutions to employers and their employees. The firm provides a range of healthcare tools, year-round employee advocacy, and continuous measurement to assess and recommend healthcare plans. By focusing on these aspects, Nava helps clients manage their employee benefits effectively while reducing overall plan costs. This approach allows businesses to offer the necessary benefits to their workforce, ensuring both accessibility and affordability in healthcare coverage.

FarmWise

Series B in 2022
FarmWise Labs, Inc. develops innovative robotic machinery aimed at enhancing agricultural efficiency. Founded in 2016 and based in San Francisco, the company specializes in autonomous cultivation solutions, particularly focusing on weeding and thinning crops. FarmWise's technology utilizes machine learning and artificial intelligence to perform essential farming tasks such as weeding, planting, sowing, and soil tilling. Their autonomous vegetable weeder is designed to minimize the use of herbicides, allowing farmers to cultivate healthier crops while improving overall productivity. By streamlining farm operations, FarmWise aims to support sustainable farming practices and increase food production efficiency.

Mirvie

Series B in 2022
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.

OMass Therapeutics

Series B in 2022
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.

Celsius Therapeutics

Series B in 2022
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.

Spotlight Therapeutics

Series B in 2022
Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Nothing

Series B in 2022
Nothing is removing the barriers between people and technology to create a seamless digital future.

Redpanda

Series B in 2022
Social Media Marketing Platform.

Redpanda

Series B in 2022
Redpanda is a queue for people who deal with massive data streams.

Censys

Series B in 2022
Censys, Inc. is a cybersecurity company specializing in internet scanning and asset identification solutions. Founded in 2017 and based in Ann Arbor, Michigan, Censys provides an internet device search engine that allows users to discover and analyze devices connected to the Internet, including computers, servers, and smart devices. The platform is utilized for various applications such as attack surface management, monitoring remote workforces, and identifying potential threats. Censys is recognized for delivering real-time visibility and risk assessments, making it a valuable resource for researchers, corporations, and government entities. The company's data-driven security solutions are employed by notable organizations, including FireEye, Google, NATO, and the U.S. Department of Homeland Security, to enhance their cybersecurity measures and proactively address threats.

Leyden Labs

Series B in 2022
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Found

Series B in 2021
Found is dedicated to improving people’s overall wellbeing by making evidence based weight loss accessible & affordable for all.

Synthesia

Series B in 2021
Synthesia Ltd. develops artificial intelligence driven video production platform to create high-end videos. The company’s video synthesis platform allows to create high-end videos for many applications, including personalized advertising, corporate communications, and e-learning. Its platform synchronizes the lip movements in a video to a new dialogue track, which enables video content to be translated into foreign languages, widening distribution channels. The company was incorporated in 2017 and is based in London, United Kingdom.

Universe

Series B in 2021
Universe is a mobile-based website builder established in 2014 and headquartered in Brooklyn, New York. The platform aims to empower users to create customized websites quickly and easily, catering to the needs of small business owners and individuals who prefer mobile solutions. By offering a unique approach that eliminates complicated templates, Universe utilizes customizable website filters that allow users to arrange photos, videos, and icons on a grid pattern through a simple drag-and-drop interface. This enables users to build mobile-optimized websites in just minutes using the company's iOS app, providing them with full control over their online presence.

Upbound

Series B in 2021
Upbound, Inc. is a technology company based in Seattle, Washington, that specializes in providing a multi-cloud platform which allows organizations to manage and optimize services across various public and private cloud environments. Founded in 2017, Upbound offers solutions that enable automation, cost optimization, and policy enforcement, facilitating scalable deployments and application management. Its platform empowers organizations to treat multiple disparate cloud environments as a single cohesive unit, enhancing efficiency and reducing operational costs while ensuring portability and failover capabilities.

Ankyra

Series B in 2021
Provider of cancer therapy services intended to improve both the safety and efficacy of cytokine immunotherapies for cancer patients. The company's services offer systemic dosing of these immune stimulants that have historically been limited by broad immune activation and toxicity, develops cancer therapies based on tumor-localized immune potentiating agents that boost anti-tumor immune responses, enabling patients to find an instant treatment for cancer without any surgery.

Infinitus Systems

Series B in 2021
Developer of a healthcare AI communication tool designed to automate communication. The company's tool handles tedious, time-consuming phone calls with accuracy and easy-to-track updates, facilitates users to seamlessly submit call requests to the system and adds their tasks to the queues, enabling users to get notified as soon as each task completes or bulk-collect their results whenever needed.

StrongDM

Series B in 2021
strongDM manages and audits access to servers and databases. It provides a single platform to control access to any database for employees, vendors, and cloud-based tools. The company was awarded in the Strata+Hadoop World Audience Favorite in 2016. It was incorporated in 2015 and is headquartered in Burlingame, California.

ROME Therapeutics

Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.

Ultromics

Series B in 2021
Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.

Sonoma Biotherapeutics

Series B in 2021
Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Prime Medicine

Series B in 2021
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Physna

Series B in 2021
Physna LLC is a software company based in Cincinnati, Ohio, founded in 2015. It specializes in developing a geometric search engine that enhances computer-aided design (CAD) and 3D printing processes. The platform utilizes proprietary algorithms and advanced geometric deep learning technology to transform 3D models into a structured data format, facilitating comparison and analysis for quality control and automated inspection. Physna's solutions are applicable across various industries, including manufacturing, aerospace, defense, and consumer goods, enabling clients to improve efficiency, reduce costs, and streamline inspection automation. The company's innovative approach effectively bridges the gap between physical objects and digital representations, contributing to advancements in design and manufacturing.

Brightline

Series B in 2021
Brightline is a technology-enabled behavioral health home for children and their families. Brightline delivers integrated care through innovative technology, virtual behavioral health services, and a collaborative care team focused on supporting children across developmental stages and their families.

Favor

Series B in 2021
The Pill Club is a healthcare service that specializes in delivering birth control and related products across the United States. Founded in 2014 and based in California, it operates as an online retailer and pharmacy, providing a convenient way for women to access birth control, emergency contraceptives, and wellness gifts. The Pill Club is supported by a team of medical professionals and aims to empower women by facilitating personalized healthcare experiences. It offers prescription services in 34 states and Washington D.C., ensuring widespread access to its products. With a focus on women's health and well-being, the company strives to enhance personal freedom and health ownership through its innovative telemedicine approach.

PostHog

Series B in 2021
PostHog is increasing the number of successful products in the world. We do that by providing a platform for open-source product analytics. This helps software teams understand user behaviour. We took part in Y Combinator’s W20 cohort, and had the most successful B2B software launch on HackerNews since 2012, with a product that was just 4 weeks old. Our team is a combination of former CTOs and YC founders all turned developers, alongside some of the best developers from the world's largest tech companies who have the experience to help us handle scalability. We're all remote, and we've raised enough to pay top of market. We are proudly backed by some of the best VCs and Investors in the world, such as Y Combinator. We believe in product-led growth, while we build something awesome and let our product bring the users, rather than an outbound sales team and regular cold calls. Check out posthog.com/careers if you want to be part of this journey.

Merlin Labs

Series B in 2021
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.

Overture Life

Series B in 2021
Overture Life, Inc. is a New York-based company that specializes in developing robotic technologies for in vitro fertilization (IVF) applications. Founded in 2017, Overture Life aims to transform embryology through its innovative reproduction automation technology. The company's products focus on automating key processes in IVF, including devices for automated cryopreservation and embryo testing services. These advancements enable fertility clinics to identify viable embryos prior to implantation, thereby assisting individuals and couples in their efforts to conceive.

oneNav

Series B in 2021
OneNav is a technology company based in Palo Alto, California, co-founded by Stephen Poizner and Paul McBurney in 2019. The company specializes in developing a mobile positioning system tailored for smartphones, wearables, and IoT tracking devices. Utilizing the modernized L5 signaling band from navigation satellite constellations and incorporating artificial intelligence, OneNav's system delivers enhanced, data-rich signals that ensure accurate and reliable tracking applications for its clients.

Smol

Series B in 2021
Smol Limited, established in 2017 and based in Crawley, United Kingdom, specializes in the manufacturing of eco-friendly laundry capsules, dishwasher tablets, and fabric conditioners. The company operates primarily through a subscription model, delivering its products directly to customers' homes via letterboxes, which enhances convenience and accessibility. Smol's offerings are designed to be compact, water-soluble, and made from recycled materials, providing an environmentally friendly alternative to conventional cleaning products. By undercutting the prices of leading brands, Smol aims to deliver effective cleaning solutions while promoting sustainable practices in household cleaning.

Headway

Series B in 2021
Headway is a New York-based mental healthcare system provider that connects patients with therapists through a health insurance advisory platform. Founded in 2019 by Andrew Adams, Jake Sussman, Dan Ross, and Kevin Chan, the company aims to make mental healthcare more accessible and affordable. It operates a virtual network of therapists who accept insurance, allowing patients to schedule video or in-person sessions online. In addition to its mental health services, Headway also offers administrative support to therapists who typically do not accept insurance, thereby facilitating the expansion of their practices. By streamlining the connection between patients and providers, Headway seeks to improve the overall accessibility of mental health services.

Affinia Therapeutics

Series B in 2021
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Outlier

Series B in 2021
Outlier.org Inc. develops an online educational platform. It offers Outlier.org, a platform that provides online courses on calculus and psychology. The company’s platform also provides video content, online textbooks, one-on-one tutoring, artificial intelligence-proctored assessments, problem sets, and active learning techniques. Outlier.org Inc. was formerly known as Outlier School Inc. The company was incorporated in 2018 and is based in Brooklyn, New York.

Ventus Therapeutics

Series B in 2021
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

Snorkel

Series B in 2021
Snorkel AI, Inc. is a technology company that specializes in developing an end-to-end machine-learning platform aimed at facilitating the creation, management, and monitoring of AI applications. Central to its offerings is Snorkel Flow, a data-first platform that enables users to programmatically label and augment training data, manage data for AI purposes, and deploy various machine learning models. The platform is particularly effective in extracting entities and structured information from complex documents, making it valuable across multiple sectors, including finance, government, telecommunications, healthcare, and e-commerce. Snorkel AI's innovative approach incorporates weak supervision technology, allowing both developers and non-developers to focus on data-related tasks efficiently. Founded in 2016 and headquartered in Palo Alto, California, Snorkel AI also contributes to the academic community by publishing peer-reviewed research on its core technologies.

Lightmatter

Series B in 2021
Lightmatter, Inc. is an artificial intelligence (AI) hardware company based in Boston, Massachusetts, that specializes in integrated optical technology to develop advanced computing processors. Founded in 2017, the company has created a silicon chip that utilizes light signals for processing, offering a new approach to AI computation. This technology accelerates critical operations in deep neural networks by employing programmable photonic elements alongside traditional transistors, enhancing the speed and efficiency of data processing while minimizing power consumption. Lightmatter's innovations aim to improve various AI applications, including image recognition and natural language processing, contributing to the advancement of next-generation AI-powered computing solutions.

Genesis Global

Series B in 2021
GENESIS Global was originally started by a team of industry leaders in the Global Financial Markets space with extensive experience in front to back trading technologies across multiple asset classes and business lines. The members of their management and advisory team have held senior global management roles at investment banks around the world and at trading technology software vendors. Extensive experience with global financial technology vendors. They have a simple strategy, to be a global FinTech company providing best in class solutions and services which are in line with their client’s needs, goals and expectations. They have a disruptive framework technology and business model to achieve this strategy.

Dandelion Energy

Series B in 2021
Dandelion Energy, Inc., founded in 2017 and headquartered in Palo Alto, California, specializes in affordable geothermal heating and cooling solutions for residential properties. The company's innovative home geothermal system replaces traditional air conditioning and heating equipment with a heat pump and underground pipes that efficiently transfer thermal energy between the earth and the home. This proprietary installation process allows homeowners to transition from conventional heating fuels to renewable geothermal energy, providing an environmentally friendly and cost-effective alternative for temperature regulation and hot water production.

Multiverse

Series B in 2021
Multiverse offers apprenticeship opportunities tailored for non-graduate individuals, positioning itself as an alternative to traditional university education. Founded in 2016 and based in London, the company focuses on providing career-oriented apprenticeships that empower young people to take charge of their professional journeys. By facilitating access to high-quality training and resources, Multiverse aims to create a fulfilling career path for its participants, moving away from conventional corporate training methods. The company also incorporates digital tools to help apprentices build their profiles and engage in social networking, enhancing their learning experience and career prospects.

Verve Therapeutics

Series B in 2021
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

EQRx

Series B in 2021
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

LifeMine

Series B in 2021
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.

AMP

Series B in 2021
AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

Vercel

Series B in 2020
Vercel Inc. is a cloud platform that specializes in on-demand deployment, hosting, and sharing services for frontend applications. Founded in 2015 and based in Walnut, California, the company provides automated deployment solutions integrated with GitHub, Bitbucket, and GitLab, allowing projects to be deployed seamlessly from pull requests and merge requests. Vercel's platform is designed to enhance the development and deployment experience for frontend teams by hosting static websites and serverless functions that align with the Jamstack deployment model. This model ensures that web pages are pre-rendered and can be efficiently served by a content delivery network, delivering optimal performance for developers. Vercel was formerly known as ZEIT, Inc. before rebranding in April 2020.

Locanabio

Series B in 2020
Locanabio, Inc. develops RNA-targeted gene therapies to treat a spectrum of underserved diseases. It offers therapies for neuromuscular, neurodegeneration, and ophthalmology diseases. Locanabio, Inc. was formerly known as Locana, Inc. and changed its name to Locanabio, Inc. in July 2020. The company was founded in 2016 and is based in San Diego, California.

Hodinkee

Series B in 2020
Established in 2008, HODINKEE is the destination for all things in the world of horology. Over the past decade, ​founder Ben Clymer and team have​ grown HODINKEE into a robust media and retail platform by providing its respected point of view on industry news and releases, investing in engaging and creative storytelling, producing a designated podcast, printing a bi-annual publication, and launching and growing its own retail outlet, HODINKEE Shop. At its core, HODINKEE’s goal is to bring its readers and consumers the best in luxury products in a way that is approachable, authentic, and honest.

Resilience

Series B in 2020
Resilience is a biopharmaceutical manufacturing and technology company based in La Jolla, California, established in 2020. It aims to enhance access to complex medicines and safeguard biopharmaceutical supply chains. The company specializes in end-to-end manufacturing and development solutions across various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience provides customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals at all stages of the drug development process, from pre-clinical development to commercial supply. With a focus on developing new manufacturing technologies, Resilience ensures high-quality and regulatory-compliant processes for complex and novel medicines.

Invivyd

Series B in 2020
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Superplastic

Series B in 2020
Superplastic, Inc. is a character-based product and entertainment company founded in 2017 and based in Burlington, Vermont. The company specializes in manufacturing and marketing limited edition art toys, apparel, games, and animation, featuring unique characters created in collaboration with renowned artists. Superplastic leverages the principles of effort and scarcity to enhance the value of its offerings, creating exclusive works of art for a select audience. The company also operates a platform that engages customers through various media, including animated videos and music, enabling interactions with its synthetic superstars in innovative ways. Products are primarily sold online, reflecting a modern approach to retail and entertainment.

Alkira

Series B in 2020
Alkira, Inc. is a network cloud company that offers an end-to-end networking platform designed for hybrid and multi-cloud environments. Founded in 2018 and based in San Jose, California, Alkira provides its services through a pay-as-you-go model, allowing customers to connect their local systems and cloud workloads to the Alkira Cloud Exchange Points. The platform enables on-demand activation of security and other services that can auto-scale based on utilization. Alkira's Network Cloud solution allows businesses to easily create and manage their network infrastructure using an intuitive digital design canvas, facilitating rapid deployment. The company serves a diverse clientele, including Fortune-100 enterprises and leading managed service providers, by delivering integrated network and security services along with operational visibility and governance.

Tend

Series B in 2020
Tend offers personalized dental care services that emphasize patient comfort and satisfaction. The company operates dental studios that provide a comprehensive range of services, including routine checkups, implants, and veneers. Tend aims to enhance the patient experience by ensuring safety through health checks, contactless check-in, and the use of enhanced personal protective equipment. By focusing on straightforward and hassle-free dental care, Tend strives to deliver accurate diagnoses and high-quality restorations, making dental visits more efficient and enjoyable for patients.

Monte Rosa Therapeutics

Series B in 2020
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Taysha Gene Therapies

Series B in 2020
Taysha Gene Therapies is a company focused on developing adeno-associated virus (AAV) based gene therapies aimed at treating monogenic diseases of the central nervous system. Founded in 2019 and based in Dallas, Texas, the company is advancing several therapeutic candidates, including TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies collaborates with The University of Texas Southwestern Medical Center to enhance the development and commercialization of its innovative treatments, with a mission to eradicate severe and life-threatening CNS diseases through curative gene therapies. The company's expertise in drug development and its partnership with a leading gene therapy program enable it to effectively progress its pipeline of potential therapies.

Kindbody

Series B in 2020
Kindbody is a health and technology company focused on providing comprehensive fertility services tailored for modern women. Their offerings include intrauterine insemination, in-vitro fertilization, egg and embryo freezing, as well as support for donors. In addition to fertility treatments, Kindbody provides a range of holistic health services, including maternity care, gynecology, and wellness support. By leveraging modern technology, Kindbody aims to improve access to affordable healthcare, ensuring that women can receive quality services that enhance their overall health and wellbeing.

insitro

Series B in 2020
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.

Digits

Series B in 2020
Digits Financial, Inc. is a fintech company founded in 2018 and based in San Francisco, California. The company specializes in developing software that offers a real-time view of a business's finances. Its platform streamlines the creation of financial reports and transaction records, significantly reducing manual workload. By visualizing and managing financial data, Digits enhances interactions between businesses and their accountants, investors, and advisors. This innovative approach positions Digits as a key player in providing modern financial solutions for businesses.

Accent Therapeutics

Series B in 2020
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.

Cerevance

Series B in 2020
Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.

Ready

Series B in 2020
Ready Responders, Inc. focuses on enhancing community health by providing immediate medical care and support for various health needs. Founded in 2016 and headquartered in New Orleans, Louisiana, the company offers services such as 911 quick responses, telehealth consultations, and patient access to emergency medical professionals. Their responders visit patients at home to address physical, mental, and social health needs, utilizing technology to connect with advanced medical providers. Ready Responders also facilitates connections to external resources for ongoing support and aims to improve patient experiences while reducing overall care costs. The company operates in multiple locations across Louisiana, Nevada, New York City, and the National Capital Region, and is in-network with many major insurance providers.

Ripcord

Series B in 2020
Ripcord, Inc., a robotic digitization company, develops automation software for robotic digitization. It offers Canopy, a solution that uses artificial intelligence and machine learning to capture, enrich, and organize its customers’ important content; and enables enterprises to streamline their business processes. Ripcord, Inc. was formerly known as Ripcord Digital, Inc. and changed its name to Ripcord, Inc. in June 2017. The company was founded in 2014 and is headquartered in Los Angeles, California.

TScan Therapeutics

Series B in 2020
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.

Viz

Series B in 2019
Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

IonQ

Series B in 2019
IonQ, Inc. specializes in the development of general-purpose quantum information computers, utilizing a unique trapped ion approach. The company's technology combines high physical performance, perfect qubit replication, and optical networkability, enabling the creation of scalable quantum computers that surpass the limitations of classical computing. These advancements leverage phenomena such as superposition and entanglement, which are critical at the atomic scale. Founded in 2015 and headquartered in College Park, Maryland, IonQ aims to support a wide range of applications across various industries with its powerful and versatile quantum computing solutions.

Lovevery

Series B in 2019
Lovevery, Inc. is a company based in Boise, Idaho, that specializes in manufacturing educational play products for infants. Founded in 2015, Lovevery offers a range of items designed to support early childhood development, including the Play Gym, which features various toys and tools that engage babies' senses and promote learning at different developmental stages. The company's products are informed by child development experts and aim to provide parents with stage-based information to enhance their children's growth. Lovevery sells its offerings primarily online and has received recognition for its innovative designs from several notable organizations, including TIME Magazine and Parents' Choice. The company is backed by prominent investors such as Maveron and the Chan Zuckerberg Initiative.

Tenaya Therapeutics

Series B in 2019
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Kitchen United

Series B in 2019
Kitchen United, Inc. is a company that provides food production facilities specifically designed for restaurants and food service providers. Founded in 2017 and headquartered in Pasadena, California, it offers shared commercial kitchen spaces along with business intelligence solutions to support entrepreneurial caterers, pop-ups, mobile food vendors, and start-ups. By providing a turnkey solution, Kitchen United helps restaurant brands expand their operations with minimal risk and investment. Its facilities enable these businesses to efficiently produce food for pick-up and delivery, facilitating their entry into the food delivery market. The company operates locations in major cities across the United States, including Austin, Chicago, Los Angeles, San Francisco, New York City, and Scottsdale.

Snyk

Series B in 2019
Snyk Ltd. is a developer-focused cybersecurity company that provides a software-as-a-service platform designed to help organizations identify, fix, and monitor vulnerabilities in open-source dependencies and container images. The platform includes tools such as Snyk Code, which offers static application security testing, and container vulnerability management, which addresses vulnerabilities in Docker images. Snyk enables developers to scan their code for security issues directly within their code editors, providing alerts and remediation guidance based on an internal database of known vulnerabilities. The company also offers features for application security management, licensing compliance, and infrastructure as code security. Founded in 2015 and headquartered in London, Snyk has additional offices in Tel Aviv, Boston, and Ontario, and has established a strategic partnership with Rapid7, Inc.

Homebound

Series B in 2019
Homebound Inc. is a technology-driven custom home builder based in Santa Rosa, California, founded in 2017. The company specializes in constructing residential homes and offers a comprehensive range of support services, including architecture, design, financing, and insurance consultancy. Originating in response to the 2017 Northern California wildfires, Homebound aims to simplify the homebuilding process by providing a transparent and streamlined experience for homeowners. It manages the entire building journey, assisting clients from insurance negotiation and architectural design to permitting and construction. By leveraging user-friendly technology and a network of qualified building professionals, Homebound addresses the complexities and uncertainties homeowners face, particularly in the aftermath of natural disasters, enabling them to rebuild their homes more efficiently.

Freenome

Series B in 2019
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

TScan Therapeutics

Series B in 2019
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.

Blackthorn Therapeutics

Series B in 2019
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Instawork

Series B in 2019
Instawork operates an online job marketplace designed to connect hospitality businesses with qualified workers. The platform automates the recruitment process, allowing businesses to fill job shifts on demand while enabling professionals to choose work that fits their schedules. By streamlining traditional recruiting methods, Instawork creates economic opportunities for both local businesses and workers. The company is rapidly expanding its reach across the United States, focusing on meeting the evolving needs of the hospitality sector.

Sense

Series B in 2019
Sense is an automated communication and engagement platform specifically designed for enterprise recruiting teams and the staffing industry. The platform aims to enhance talent engagement by providing tools that help reduce turnover and increase re-deployment rates. It offers a real-time, comprehensive view of consultants, enabling organizations to better understand their workforce dynamics. Based in San Francisco, Sense has attracted investment from notable venture capital firms, including Accel, GV, Khosla Ventures, Signia Ventures, and IDG SF.

Harness

Series B in 2019
Harness, Inc. is a technology company that offers a Continuous Delivery-as-a-Service platform designed to simplify the process of deploying code from artifact to production. Founded in 2015 and based in San Francisco, California, Harness utilizes machine learning to automate the continuous delivery process, thereby enhancing efficiency and security for engineering and DevOps teams. Its platform features a variety of tools including a pipeline builder, workflow wizard, continuous verification, automated rollback, secrets management, audit trails, and real-time delivery analytics. This comprehensive approach aims to streamline application releases while providing robust protection against deployment failures.

Arrakis Therapeutics

Series B in 2019
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.

SambaNova Systems

Series B in 2019
SambaNova Systems is a computing startup focused on building machine learning and big data analytics platforms. The company's software defined analytics platform enables optimum performance for any ML training, inference or analytics models.

Lambda

Series B in 2019
Lambda Inc., operating as Lambda School, specializes in online education focused on coding and computer science in the United States. Founded in 2016 and based in San Francisco, the institution offers training in various fields, including software engineering, artificial intelligence, machine learning, and web development. Students engage in both online and live training sessions that feature hands-on projects, pair programming, and code reviews conducted by instructors. Lambda School aims to identify and cultivate untapped talent for in-demand jobs, pioneering a unique educational model where the institution invests in students' futures rather than requiring upfront tuition payments.

Beam Therapeutics

Series B in 2019
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

Obsidian Security

Series B in 2019
Obsidian Security, Inc. is a technology company based in Newport Beach, California, specializing in cybersecurity solutions tailored for hybrid-cloud environments. Founded in 2017 by former members of renowned companies in the security sector, Obsidian Security focuses on leveraging artificial intelligence to address cyber threats. Its platform provides comprehensive services, including threat detection, breach remediation, and security hardening specifically for software as a service (SaaS) applications. The company's offerings aim to deliver intelligent identity protection and seamless security, enabling enterprises to safeguard their interconnected systems without hindering productivity. Backed by notable investors, Obsidian Security positions itself at the forefront of the evolving cybersecurity landscape.

Cmd

Series B in 2019
Cmd is a developer of a server security platform focused on protecting production environments in Linux. The platform provides organizations with real-time visibility into user actions and customizable controls, enabling the pre-execution blocking of potentially harmful commands without human intervention. This proactive approach helps organizations address common security hygiene issues and mitigate the risk of breaches, allowing them to effectively manage user behavior in cloud-first environments. Cmd's solution facilitates collaboration between DevOps and SecOps teams, enhancing overall security while minimizing disruptions to business operations.

2nd Address

Series B in 2019
With thousands of diverse and premium apartments, condos, and houses in major business centers across the U.S., 2nd Address eases the anxiety of business travel. Our online experience makes finding, leasing, and managing properties simpler and provides a richer experience for Guests as they settle into their new temporary home. Our customers include Google, Facebook, Microsoft and thousands of smaller businesses. Founded in 2014, we operate across the United States with a specific focus in large urban markets.

Favor

Series B in 2019
The Pill Club is a healthcare service that specializes in delivering birth control and related products across the United States. Founded in 2014 and based in California, it operates as an online retailer and pharmacy, providing a convenient way for women to access birth control, emergency contraceptives, and wellness gifts. The Pill Club is supported by a team of medical professionals and aims to empower women by facilitating personalized healthcare experiences. It offers prescription services in 34 states and Washington D.C., ensuring widespread access to its products. With a focus on women's health and well-being, the company strives to enhance personal freedom and health ownership through its innovative telemedicine approach.

Lambda

Series B in 2019
Lambda Inc., operating as Lambda School, specializes in online education focused on coding and computer science in the United States. Founded in 2016 and based in San Francisco, the institution offers training in various fields, including software engineering, artificial intelligence, machine learning, and web development. Students engage in both online and live training sessions that feature hands-on projects, pair programming, and code reviews conducted by instructors. Lambda School aims to identify and cultivate untapped talent for in-demand jobs, pioneering a unique educational model where the institution invests in students' futures rather than requiring upfront tuition payments.

RightHand Robotics

Series B in 2018
RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.

Bowery

Series B in 2018
Bowery Farming Inc. is a modern agricultural company based in New York City, specializing in the cultivation of post-organic produce such as baby kale, lettuce, arugula, and basil. Founded in 2014, Bowery employs advanced technology, including its proprietary BoweryOS software, to create optimal growing conditions in indoor farms. This system utilizes automation, machine learning, and vision systems to monitor plant growth continuously, resulting in highly efficient farming practices. Bowery's operations use zero pesticides and consume 95% less water while achieving over 100 times the productivity of traditional farming methods on the same land area. The company sells its products through grocery stores, including select Whole Foods and Foragers locations, and supplies produce to various restaurants, including those owned by renowned chef Tom Colicchio. Bowery Farming is committed to transforming agriculture to ensure a sustainable and healthier food supply for the future.

Happiest Baby

Series B in 2018
Happiest Baby, Inc. is a technology company focused on enhancing child well-being through science-based products and services aimed at addressing everyday parenting challenges. Founded in 2001 by pediatrician Dr. Harvey Karp and his wife Nina Montée-Karp, the company is headquartered in Santa Monica, California. Its flagship product, the SNOO, is the world's first smart sleeper, utilizing advanced robotic technology to soothe infants based on Dr. Karp's established 5 S’s method. The SNOO is designed to reduce crying, promote better sleep, and ensure safety by preventing infants from rolling over. In addition to the SNOO, Happiest Baby offers a range of baby swaddles, sacks, sheets, and educational materials, including books and guides on baby care. The company primarily sells its products online and collaborates with notable investors and parent advisors to support families both in the United States and internationally.

HeadSpin

Series B in 2018
HeadSpin is a digital experience intelligence platform that aims to deliver flawless digital experiences by integrating automation, artificial intelligence, and analytics. The platform facilitates end-to-end testing, performance optimization, and experience monitoring, utilizing a global infrastructure of devices deployed in over a hundred locations on real carrier and WiFi networks. This comprehensive approach allows engineering, quality assurance, operations, and product teams to remotely test and monitor mobile applications effectively. By ensuring optimal digital experiences throughout the development lifecycle, HeadSpin helps organizations enhance their operational efficiency and potentially increase revenue.

Ethos Life

Series B in 2018
Ethos Life is an insurance company based in San Francisco, California, that specializes in providing modern and ethical life insurance products, primarily term life insurance. Founded in 2016, Ethos aims to make life insurance affordable, accessible, and instant, addressing a significant market valued at $650 billion. The company employs innovative software to enhance the customer experience and utilizes technology to tailor coverage to individual needs. Ethos policies are issued and guaranteed by Legal & General America, a well-established life insurance provider. The company emphasizes a human approach in its services, striving to protect families through personalized insurance solutions.

Resolution Games

Series B in 2018
Resolution Games AB is a gaming studio based in Stockholm, Sweden, founded in 2015. The company specializes in developing virtual reality (VR) and augmented reality (AR) games, aiming to create immersive experiences for players. With a team of industry experts, Resolution Games focuses on producing a diverse catalog of titles that enhance the sense of presence and engagement through cutting-edge technology. The studio's games are designed to be available across multiple platforms, catering to a wide audience of gaming enthusiasts.

Snyk

Series B in 2018
Snyk Ltd. is a developer-focused cybersecurity company that provides a software-as-a-service platform designed to help organizations identify, fix, and monitor vulnerabilities in open-source dependencies and container images. The platform includes tools such as Snyk Code, which offers static application security testing, and container vulnerability management, which addresses vulnerabilities in Docker images. Snyk enables developers to scan their code for security issues directly within their code editors, providing alerts and remediation guidance based on an internal database of known vulnerabilities. The company also offers features for application security management, licensing compliance, and infrastructure as code security. Founded in 2015 and headquartered in London, Snyk has additional offices in Tel Aviv, Boston, and Ontario, and has established a strategic partnership with Rapid7, Inc.

mabl

Series B in 2018
Mabl Inc. offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. Founded in 2016 and based in Boston, Massachusetts, the company provides a scriptless testing solution as part of its software-as-a-service (SaaS) offerings. Mabl facilitates machine-driven regression testing and integrates seamlessly into the continuous integration and continuous delivery (CI/CD) development lifecycle. Its platform allows software development teams to create, execute, and maintain auto-healing tests efficiently, ensuring the rapid delivery of high-quality applications. Mabl serves a range of enterprise clients, including Johnson Controls, Liberty Mutual, Molina Healthcare, JetBlue, Dollar Shave Club, and Charles Schwab, who rely on its services for testing their critical applications.

StockX

Series B in 2018
StockX operates a live bid/ask marketplace for buying and selling limited edition and high demand sneakers. Its marketplace enables users to anonymously buy and sell limited edition consumer products with stock market-like visibility. StockX’s platform allows users to create their own personalized sneaker portfolio by uploading their current collection and compare and contrast their sneaker collection to other users on the platform. The company was founded in March 2015, with its headquarters in Detroit in Michigan.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.